ImmPACT Bio Ltd.

immpact-bio.com

High-Tech Company

Acquired by Lyell

Graduated from: FutuRx

TECH VERTICALS

Biotechnology, Life Sciences, MedTech, Therapeutics

General Data

Sector	Biomed
Company Stage:	R&D
Established	2017
Number of Employees	108
Employees in Israel	4
Reg. Number:	abCDe

DESCRIPTION

ImmPACT Bio is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies for cancer patients who have exhausted their treatment options. The company’s logic-gate-based CAR T platforms address key biological challenges in treating cancer. ImmPACT Bio’s technologies are specifically designed to prevent antigen escape, prevent ‘on-target – off-tumor’ toxicities, and overcome the immunosuppressive tumor microenvironment. The company’s technology is based on the work of pioneering scientists Yvonne Chen, Ph.D., and Antoni Ribas, M.D., Ph.D., both from University of California, Los Angeles (UCLA), and Gideon Gross, Ph.D., from the MIGAL-Galilee Research Institute.

TECHNOLOGY

CAR-T cells

Products and Phases

Product	Phase
ImmPACT-Bio Chimeric Antigen Receptor T-cell (CAR-T) therapy targeting CD19/20	Phase II
CAR-T cells for cancer immunotherapy.

	TARGET MARKETS
	Cancer patients, Oncologists

	BUSINESS MODEL
	B2C

REMARKS

Date	Remark
31/10/2024	No Israeli presence following the acquisition by Lyell Immunopharma.

CONTACT INFO

Expand / Collapse All

Main Address: Camarillo, United States

Address	4010 Adolfo Rd,
City	Camarillo
State/Province	CA
Country	United States
Zip	93012

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Rehovot, Israel

Address	2 E.D. Bergman St.
City	Rehovot
Country	Israel
Zip	7670503

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title
Prof. Gideon Gross	Founder

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Acquired

Oct. 31, 2024

R&D

abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

Second Round

Jan. 20, 2022

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Corporate VC	abCDe
abC Defghij	Private Equity Fund	abCDe	Round co-leader
abC Defghij	Private Equity Fund	abCDe	Round co-leader
abC Defghij	Investment Company	abCDe	Round co-leader
abC Defghij	Investment Company	abCDe
abC Defghij	High-Tech Company	abCDe

First Round

Aug. 18, 2020

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe	Led the round
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Corporate VC	abCDe
abC Defghij	Corporate VC	abCDe
abC Defghij	Corporate VC	abCDe
abC Defghij	Corporate VC	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	High-Tech Company	abCDe

Seed

May. 01, 2017

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Technology Transfer Company	abCDe
abC Defghij	Government Agency	abCDe	R&D Grant
abC Defghij	Incubator	abCDe

	Acquisitions made by ImmPACT Bio

Acquired Company	Sector	Date	Amount	Remarks
abC Defghij	Biomed...	Jul. 07, 2021	abCDe

Last Updated:	abCDe
IVC Number:	abCDe